恶性腹膜间皮瘤在米兰国家癌症中心的治疗进展

弥漫性恶性腹膜间皮瘤（diffuse malignant peritoneal mesothelioma，DMPM）是一种源自腹膜间皮细胞、高度恶性的罕见原发性恶性肿瘤，本文对DMPM的定义、诊断、患者管理流程、米兰国家癌症中心肿瘤细胞减灭术（cytoreductive surgery，CRS）联合腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy，HIPEC）治疗数据、围手术期化疗对患者预后影响、多囊型腹膜间皮瘤治疗建议、乳头状腹膜间皮瘤治疗建议等进行概述。对本中心DMPM认识与治疗经验进行介绍。随着对这类肿瘤疾病的临床特征和生物学特性进行广泛研究，发现可切除性DMPM应接受CRS+HIPEC，可能会改变患者的自然病程。 

Advances in treatment of malignant peritoneal mesothelioma at National Cancer Institute of Milan

Diffuse malignant peritoneal mesothelioma (DMPM) is a rare primarymalignant neoplasmoriginatingfrom peritoneal mesothelial cells.The purpose of this study is to summarize the definition, diagnosis, patient management process, and Milan cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) treatment data for DMPM. Furthermore, we examine the prognosis effect of perioperative chemotherapy on DMPMpatients as well as the treatment recommendations for polycystic peritoneal mesothelioma and papillary peritoneal mesothelioma. We also describe theMilan’s understanding of DMPMand experience with its treatment.By studying the clinical and biological characteristics of DMPM, the evidence indicates that resectableDMPM should receive CRS-HIPEC treatment, which may alter the patient’s natural disease course.